BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 9050883)

  • 1. Targeting RNA decay with 2',5' oligoadenylate-antisense in respiratory syncytial virus-infected cells.
    Cirino NM; Li G; Xiao W; Torrence PF; Silverman RH
    Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1937-42. PubMed ID: 9050883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection.
    Barnard DL; Sidwell RW; Xiao W; Player MR; Adah SA; Torrence PF
    Antiviral Res; 1999 Apr; 41(3):119-34. PubMed ID: 10320045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting RNase L to human immunodeficiency virus RNA with 2-5A-antisense.
    Player MR; Maitra RK; Silverman RH; Torrence PF
    Antivir Chem Chemother; 1998 May; 9(3):225-31. PubMed ID: 9875401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense.
    Leaman DW; Longano FJ; Okicki JR; Soike KF; Torrence PF; Silverman RH; Cramer H
    Virology; 2002 Jan; 292(1):70-7. PubMed ID: 11878909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA.
    Player MR; Barnard DL; Torrence PF
    Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8874-9. PubMed ID: 9671772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin.
    Xu Z; Kuang M; Okicki JR; Cramer H; Chaudhary N
    Antiviral Res; 2004 Mar; 61(3):195-206. PubMed ID: 15168801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-5A-antisense chimeras: inhibitors of respiratory syncytial virus infection.
    Torrence PF
    Curr Opin Mol Ther; 1999 Jun; 1(3):307-15. PubMed ID: 11713795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells.
    Maran A; Waller CF; Paranjape JM; Li G; Xiao W; Zhang K; Kalaycio ME; Maitra RK; Lichtin AE; Brugger W; Torrence PF; Silverman RH
    Blood; 1998 Dec; 92(11):4336-43. PubMed ID: 9834240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides.
    Jairath S; Vargas PB; Hamlin HA; Field AK; Kilkuskie RE
    Antiviral Res; 1997 Feb; 33(3):201-13. PubMed ID: 9037376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlling gene expression with 2-5A antisense.
    Leaman DW; Cramer H
    Methods; 1999 Jul; 18(3):252-65. PubMed ID: 10454983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-5A antisense treatment of respiratory syncytial virus.
    Leaman DW
    Curr Opin Pharmacol; 2005 Oct; 5(5):502-7. PubMed ID: 16081320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of selective modifications to a 2',5'-oligoadenylate-3',5'-deoxyribonucleotide antisense chimera with affinity for the target nucleic acid and with ability to activate RNase L.
    Xiao W; Li G; Maitra RK; Maran A; Silverman RH; Torrence PF
    J Med Chem; 1997 Apr; 40(8):1195-200. PubMed ID: 9111293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recruiting the 2-5A system for antisense therapeutics.
    Torrence PF; Xiao W; Li G; Cramer H; Player MR; Silverman RH
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):203-6. PubMed ID: 9212911
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemistry and biochemistry of 2',5'-oligoadenylate-based antisense strategy.
    Adah SA; Bayly SF; Cramer H; Silverman RH; Torrence PF
    Curr Med Chem; 2001 Aug; 8(10):1189-212. PubMed ID: 11472236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The quest for an efficacious antiviral for respiratory syncytial virus.
    Torrence PF; Powell LD
    Antivir Chem Chemother; 2002 Nov; 13(6):325-44. PubMed ID: 12718405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid-phase synthesis of 5'-triphosphate 2'-5'-oligoadenylates analogs with 3'-O-biolabile groups and their evaluation as RNase L activators and antiviral drugs.
    Thillier Y; Stevens SK; Moy C; Taylor J; Vasseur JJ; Beigelman L; Debart F
    Bioorg Med Chem; 2013 Sep; 21(17):5461-9. PubMed ID: 23810677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy of respiratory syncytial virus by 2-5A antisense.
    Cramer H; Okicki JR; Kuang M; Xu Z
    Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):497-501. PubMed ID: 16247978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting RNA for degradation with a (2'-5')oligoadenylate-antisense chimera.
    Torrence PF; Maitra RK; Lesiak K; Khamnei S; Zhou A; Silverman RH
    Proc Natl Acad Sci U S A; 1993 Feb; 90(4):1300-4. PubMed ID: 7679499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalytic cleavage of an RNA target by 2-5A antisense and RNase L.
    Maitra RK; Li G; Xiao W; Dong B; Torrence PF; Silverman RH
    J Biol Chem; 1995 Jun; 270(25):15071-5. PubMed ID: 7797490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (2'-5')Oligoadenylate and intracellular immunity against retrovirus infection.
    Schröder HC; Suhadolnik RJ; Pfleiderer W; Charubala R; Müller WE
    Int J Biochem; 1992; 24(1):55-63. PubMed ID: 1374726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.